natgillin/translations-raw huggingface dataset:
A pharmaceutical formulation according to claim 9 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight). 
Farmaceutska formulacija u skladu s patentnim zahtjevom 5, naznačena time što je farmaceutski prihvatljiva kiselina metansulfonska kiselina, a sadržaj odgovarajućih nečistoća formule (IIa) ili (IIb) u obliku soli s metansulfonskom kiselinom je niži od 0,01% (težinski).
o Assay is stopped by spinning plates sealed with plate covers at 2500 rpm for 20 minutes at 22° C 
Ispitivanje se zaustavlja spinom ploča zatvorenih sa poklopcem ploče pri 2500 okr./min. tijekom 20 minuta na 22C.
An emetic based on one or more constituents of radix ipecacuanha (ipecac root), preferably based on the constituent emetine may preferably be considered in the dosage form according to the invention, as are, for example, described in “Pharmazeutische Biologie—Drogen und ihre Inhaltsstoffe” by Prof. Dr. Hildebert Wagner, 2nd, revised edition, Gustav Fischer Verlag, Stuttgart, New York, 1982. 
U obliku davanja prema izumu u obzir može pogodno doći emetik na bazi jednog ili više sastojaka od korijena ipecacuanhae (korijen koji izaziva povraćanje), prvenstveno na bazi sastojka emetina, kako je na pr. opisano kod prof. dr. Hildebert Wagner u "Pharmazeutische Biologie-Drogen und ihre Inhaltsstoffe", prerađeno izdanje, naklada Gustav Fischer, Stuttgart, New York 1982.
no-reflow phenomenon following reperfusion, a disease associated with decreased skeletal muscle blood flow, preferably Raynaud's phenomenon or intermittent claudication, 
(f) bolest povezana sa smanjenim protokom krvi u skeletnim mišićima, poželjno Raynaudov fenomen ili intermitentna klaudikacija, pri čemu se navedeno liječenje sastoji od davanja spoja navedenom pacijentu.
The binding molecule capable of binding L1 for use according to claim 8, wherein the patient is at least partially resistant to the treatment with said chemotherapeutic drug or with radiotherapy. The binding molecule capable of binding L1, 
Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 8, naznačena time što je pacijent u najmanju ruku djelomično otporan na liječenje navedenim kemoterapijskim lijekom ili Tadioterapijom.
The results are shown in table 13 and are expressed as percentage of animals fully protected by the treatment. 
Rezultati su prikazani u tablici 13 1 izraženi su kao postotak životinja potpuno zaštićenih liječenjem.
In accordance with this embodiment, the ozone may be pumped directly into the CPAP device 105 and/or a water reservoir tank 122 from the ozone compartment 110 through an ozone distribution line 118 that connects to the CPAP connector unit 130, for providing ozone to disinfect the CPAP device 105 . 
Uređaj CPAP (105) u skladu s patentnim zahtjevom 1, naznačen time što dodatno ima mjerač vremena ugrađen u ozonski uređaj (100) radu upravljanja radom sustava za rad s ozonom (115) i, specifičnije, otpuštanja ozona u uređaj CPAP (105).
a compound of formula I is prepared wherein R3 is hydrogen and R4 is by reacting a compound I-a with a phosphorochloridate 2a in the presence of a base yielding a phosphoramidate I-b: 
priprema spoj sa formulom I pri čemu R3 je vodik i R4 je [image] pomoću reakcije spoja I-a sa fosforokloridatom 2a u prisutnosti baze te se dobiva fosforamidat I-b: [image]
The compound according to (11) above or a pharmacologically acceptable salt thereof, wherein R8b represents a C1-C4 alkyl group. 
Spoj prema zahtjevu 10 ili njegova farmakološki prikladna sol, gdje R* predstavlja C,-C, alkil skupinu.
is selected from the group consisting of H and -C1-C3 alkyl, wherein C1-C3 alkyl is optionally substituted with 1-5 halogens; 
je izabran iz grupe koju čine H, -C1-C3 alkil i -(C(R)2)nA2, pri čemu je -C1-C3 alkil izborno supstituiran sa 1-5 halogena;
An antibody of any one of claims 1-7, a conjugate of claim 8 or a pharmaceutical composition of claim 9 for use in a method of treating or preventing a cancer disease or disorder involving a cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface in a subject. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1-6, konjugat prema patentnom zahtjevu 7 ili farmaceutska kompozicija prema patentnom zahtjevu 8 za upotrebu u postupku za liječenje ili prevenciju bolesti raka ili poremećaja koji obuhvaća stanicu koja eksprimira CLDN6 i koja je naznačena vezom CLDN6 s njezinom staničnom površinom kod subjekta.
a protein comprising an amino acid sequence having homology of at least 50% with the amino acid sequence of SEQ ID N°2 and having a fructosyl-transferase activity. 
(C) protein koji ima aminokiselinski slijed homologan najmanje 50% aminokiselinskom slijedu u SEQ ID NO:21 ima aktivnost fruktozil-transferaze.
The composition for use according to any one of claims 1 to 3, wherein the photoactivator further comprises at least one of a xanthene derivative dye, an azo dye, a biological stain, or a carotenoid. 
Kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, gdje fotoaktivator dalje sadrži najmanje jednu boju izvedenu iz ksantena, azo boju, biološku boju, ili karotenoid.
The formulation according to claim 1, wherein formulation comprises from 150 mg to 1500 mg of compound of formula (I) or its co-crystal. 
Formulacija sukladno patentnom zahtjevu 1, pri čemu formulacija sadrži od 150 mg do 1500 spoja formule (1) ili njegovog kokristala.
a compound wherein R2 and R3 each independently represent a hydrogen atom, methyl group, ethyl group, propyl group or isopropyl group, 
Medicinska oftalmološka otopina za uporabu prema Zahtjevu 1, gdje R' predstavlja atom vodika, metil skupinu, etil skupinu, izopropil skupinu ili heksil skupinu,
demapping constellation values corresponding to the at least one L1, TI, block into cell words; 
demapiranje konstelacijskih vrijednosti u skladu sa signalnim podacima Razine 1 u stanične riječi;
which upon reaction with hydrazine (QNHNH2), such as phenylhydrazine, in solvent such as EtOH, provides compounds of formula (Ih). 
O koji u reakciji s hidrazinom (QNHNH>), kao što je fenilhidrazin, u otapalu kao što je etanol, daje spojeve formule (Ih).
A light source as claimed in claim 1 or claim 2, wherein the plasma crucible is of a plurality of pieces sealed together. 
Svjetlosni izvor u skladu s onim iz patentnog zahtjeva 1 ili 2, naznačen time, da je plazmena retorta homogena.
With this embodiment of FIG. 3, two bottles 20 could be available for system 10 depending upon position of valve 94 . 
Kod izvođenja sa slike 3, dvije boce 20 su na raspolaganju za sustav, u ovisnosti o položaju ventila 94.
First of all, there is generally a delay in therapeutic effect of the SSRIs. 
U prvom redu postoji zadrška što se tiče poboljšanja simptomatike kod početka liječenja, popratna pojava koja je česta kod SSRIs.
The inelastic sealing material can be selected from the group comprising plastics, metal, fibres, paper, powder, cotton, viscous paste and foamed or sintered material and combinations thereof. 
Neelastični materijal za brtvljenje može biti odabran iz skupine koja obuhvaća plastiku, metal, vlakna, papir, prašak, pamuk, viskoznu pastu i pjenasti ili sinterizirani materijal i njihove kombinacije.
debenzylation of the compound of formula 7 to yield the compound of formula 8; wherein step (a) and step (b) are conducted in the same reaction mixture without isolation of the intermediate from step (a). 
(f)_debenzilacije spoja formule 7 kako bi se dobio spoj formule 8; pri čemu se korak (e) 1 korak (f) izvode u istoj reakcijskoj smjesi bez izdvajanja intermedijera iz koraka (e).
or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, tautomers, racemates, or polymorphs. 
N-ciklopentil-5-(1,7-dioksa-2-azaspiro[4.4]non-2-en-3-il)-1,3-dimetil-1H-pirazolo[3,4-b]piridin-4-amin (spoj br. 40), ili njegove farmaceutski prihvatljive soli, farmaceutski prihvatljivi solvati, stereoizomeri, tautomeri, racemati ili polimorfi.
The teaching of this prior document is substantially that of applying the concept of cast rolling to obtain a strip of thin thickness in three distinct process steps, the last of which is exclusively in the ferritic phase, thus excluding that the so-called “mass flow” (in other words the quantity of steel flowing in the time unit at the outlet of continuous casting) may be such to allow that an ultrathin product can be obtained in a single manufacturing step totally in the austenitic field. 
Učenje je ovog dokumenta u biti da primjena koncepta valjanja odljeva, kako bi se dobila tanka traka u tri različita koraka postupka, od kojih je zadnji ekskluzivno u feritnoj fazi čime se isključuje takozvani "maseni protok" (drugim riječima, količina čelika koja protječe u jedinici vremena na izlazu kontinuiranog lijevanja), može biti takva da omogućuje dobivanje ultra-tankog proizvoda u jednom koraku proizvodnje potpuno u austenitnom području.
Example 1, 2nd Alternative Preparation, Step 4 
, Korak 4 - Spoj 10 s ivna priprema 1, 2. aternati jera
The profiled element according to one or more of the preceding claims, characterized in that said central connection (22) is inclined downward and is provided with water drainage openings (28). 
Profilirani element prema jednom ili više od patentnih zahtjeva 4 do 8, naznačen time, da je navedena centralna spojnica (22) nagnuta prema dolje i opremljena je s otvorima za otjecanje vode.
After stirring for 10 minutes n-butyl lithium in hexane (1.6 M; 6.0 mL, 9.6 mmol) was added then stirring continued for a further ten minutes. 
Nakon 10 minuta miješanja doda sc n-butillitij u hcksanu (1,6 M; 6,0 ml, 9,6 mmol), a s miješanjem se nastavi još 10 minuta.
The liquefied gas treatment system according to claim 7, wherein the BOG supplied to the sub engine (200) is BOG that is compressed while passing through all or part of the plurality of compression cylinders (14) included in the compressor (13). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor uključuje prvi kompresor (13a) i drugi kompresor (13b), gdje se prva struja se grana u drugu struju i treću struju nakon prolaska kroz prvi kompresor.
The compound according to claim 1, wherein, in formula (1), R1 is a -CO-(CH2)n-COOH group wherein n is an integer of 1 to 4, or a salt thereof. 
Spoj prema zahtjevu 1, naznačen time, da u formuli (1) R' je skupina -CO-(CH>),-COOH gdje n je cijeli broj od 1 do 4, ili njegova sol.
The method of claim 1, wherein the therapeutic agent is a steroidal anti-inflammatory agent or a pharmaceutically acceptable salt or solvate thereof. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što je terapijsko sredstvo steroidno protuupalno sredstvo, ili njegova farmaceutski prihvatljiva sol ili solvat.
The container may also include a ring that is selectively attachable and removable from the periphery of the opening such that when the ring is coupled to the container, the user is able to drink from the container without spilling or dripping. 
Posuda također uključuje obruč koji se može pričvrstiti i ukloniti od ruba otvora, tako da kada je obruč spojen na spremnik korisnik može piti iz spremnika bez prolijevanja ili kapanja.
The sole for shoes according to claim 4, wherein said protective elements are arranged and glued in annular recesses provided on an upper face of said lower element at an upper end of each of said through holes, said annular recesses constituting said undercut regions for preventing downward extraction for said protective elements. 
Potplat za cipele u skladu s patentnim zahtjevom 4, naznačen time, da su navedeni zaštitni elementi (118) postavljeni i zalijepljeni u prstenastim upustima (124) koji se nalaze na gornjoj strani navedenog donjeg elementa
Table 23: results of analysis of the first round sequence optimization variants of IL17MS04G01 
(33) Država ili organizacija podnošenja prve prijave: US
Number of SNPs called per sample 
(21) Broj predmeta:
undesired drug interactions; cancer diseases; cellular proliferative disorders; colon carcinoma; liver carcinoma; CNS malfunctions; damage or disease; symptoms of aggression or behavioral disturbances; clinical; psychological and social consequences of brain damages; psychotic disturbances and personality disorders; dementia and/or associated syndromes; cardiovascular disease, malfunction or damage; malfunction, damage or disease of the gastrointestinal tract; malfunction, damage or disease of the respiratory system; lesion, inflammation, infection, immunity and/or convalescence; malfunction, damage or disease of the body as an abnormality in the development process; malfunction, damage or disease of the skin, of the muscles, of the connective tissue or of the bones; endocrine and metabolic malfunction, damage or disease; headaches or sexual malfunction. 
CNS poremećaji, oštećenja ili bolesti; simptomi agresije ili poremećaja u ponašanju; kliničke, psihološke i socijalne posljedice oštećenja mozga; psihotični poremećaji i poremećaji ličnosti; demencija 1 / ili povezani sindromi; kardiovaskularne bolesti, poremećaji ili oštećenja; poremećaji, oštećenja ili bolest probavnog trakta; poremećaji, oštećenja ili bolesti dišnog sustava; lezije, upale, infekcije, imunitet i / ili konvalidacija; kvar, oštećenje ili bolest tijela kao abnormalnosti u razvojnom procesu; poremećaji, oštećenja ili bolest kože, mišića, vezivnog tkiva i kostiju; endokrini i metabolički poremećaji, oštećenja ili bolest; glavobolje ili seksualni poremećaji.
The reaction was worked up by diluting the reaction solution in 1L IPAc and washing with 4 x 750mL water, then with 200mL brine. 
Reakcijska smjesa je bila dorađena Tazrjeđivanjem reakcijske otopine u 1L IPAc i isprana s 4 x 750 mL vode, tada s 200 mL slane vode.
and R11, together with the nitrogen atom they are attached to, form a cyclic amine; 
R!"iR!', zajedno s atomom dušika na koji su oni vezani, tvore ciklički amin;
The compound of any one of claims 1 to 3, the conjugate of claim 6 or 7, the nucleic acid molecule or the set of nucleic acid molecules according to claim 8, the vector or the set of vectors of claim 9, or the pharmaceutical composition of claim 11, for use in treating, ameliorating, or preventing coagulation factor deficiency in a mammalian subject, wherein the coagulation factor is selected from the group consisting of FVII, FVIIa, FVIII, FIX, and FXI. 
Spoj prema bilo kojem od zahtjeva 1 do 3, konjugat prema zahtjevu 6 ili 7, molekula nukleinske kiseline ili set molekula nukleinske kiseline prema zahtjevu 8, vektor ili set vektora prema zahtjevu 9, ili farmaceutski pripravak HR P20190494 T1 prema zahtjevu 11, za uporabu u liječenju, ublažavanju ili prevenciji nedostatka faktora zgrušavanja kod sisavca, pri čemu je faktor zgrušavanja odabran iz skupine koja se sastoji od FVII, FVIIa, FVIII, FLX i FXI.
Paragraphs of the Invention: 
(54) Naziv izuma:
receiving a notification that transmission of the error control message has begun; and 
prihvaćanja (750) obavijesti da je započeo prijenos poruke nadzora nad pogreškom.
In another embodiment, the pharmaceutical composition in the kit comprises multiple doses of a pharmaceutical composition according to the present invention wherein such pharmaceutical composition is a single dose form that comprises Compound I and one or more of the other antidiabetic compounds specified herein. 
Upotreba farmaceutske kompozicije prema bilo kojem od patentnih zahtjeva 1-38 za proizvodnju lijeka koji sadrži kombinaciju spoja I i jednog ili više antidijabetičkih spojeva koji so razlikuju od spoja I za liječenje dijabetesa tipa II, pri čemu spoj I ima formulu 45.
The patients had no complaints of skin irritation originating from the treatment. There was no report of increasing skin sensitivity. The use of an avermectin compound for the manufacture of a medicament for topical application on an affected skin area for treating hyperesthesia, paresthesia, or dolor caused by a sting by bees, wasps, hornets, yellow jackets, or fire ants on said area, said avermectin compound comprising ivermectin, avermectin A1a, avermectin A1b, avermectin A2a, avermectin A2b, avermectin B1a, avermectin B1b, avermectin B2a, avermectin B2b, or a compound having the following molecular structure: wherein R is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrose group of the following structure: wherein the broken line indicates a single or double bond; R1 is hydroxy and is present only when said broken line indicates a single bond; R2 is isopropyl or sec-butyl; and R3 is methoxy or hydroxyl. 
Uporaba spoja avermektina naznačena time da je za proizvodnju lijeka za topikalnu primjenu na zahvaćenom području kože za liječenje hiperestezije, parestezije ili bola koji su uzrokovani ubodima pčela, osa, stršljena, šumskih osa ili crvenih mrava na navedenom području, te navedeni spoj avermektina sadrži ivermektin, avermektin Ai», avermektin A;,, avermektin A,,, avermektin A», avermektin B,;,, avermektin B;,, avermektin B,,, avermektin B2, ili spoj koji ima slijedeću molekularnu strukturu: pri čemu R je 4'-(alfa-L-oleandrosil)-alfa-L-oleandroza skupina slijedeće strukture: pri čemu isprekidana crta označava jednostruku ili dvostruku vezu; R, je hidroksi 1 prisutan je samo kada navedena isprekidana crta označava jednostruku vezu; R> je izopropil ili sek-butil; te Rs je metoksi ili hidroksil.
An object of this invention also relates to the use of an AAV vector comprising a therapeutic gene for the manufacture of a medicament for treating a motor neuron disorder in a subject, wherein said AAV vector is administered by peripheral injection to said subject, said administration causing infection of (spinal cord) motor neurons and expression of the gene in (spinal cord) motor neurons. 
AAV vektor koji sadrži terapijski gen za uporabu u metodi za liječenje poremećaja motoričkih neurona u subjekta, pri čemu se navedeni AAV vektor daje intraperitonealnim (i.p.), intramuskularnim (i.m.) ili intravenskim (i.v.) injiciranjem, poželjno intravenskim injiciranjem, navedenom subjektu, navedena primjena uzrokuje infekciju motoričkih neurona ili glija stanica 1 ekspresiju gena u motoričkim neuronima ili glija stanicama, pri čemu je navedeni AAV vektor:
Use of the printing ink according to the composition as claimed in one or more of the claims 1-5. 
Uporaba tinte za tiskanje naznačena time da je u skladu s pripravkom prema jednom ili više zahtjeva 1-5.
mixing the composition obtained in step (a) with a lubricant; and 
(b) miješanje s lubrikantom sastava dobivenog u koraku (a); i
A solid cosmetic product according to claim 4 wherein the non-effervescent material comprises plant material in an amount of 5 to 30 wt% based on the non-effervescent material. 
Kruti kozmetički proizvod u skladu sa zahtjevom 4 naznačen time da ne-pjenušavi materijal sadrži biljni materijal u količimi od 5 do 30 masenih % u odnosu na ne-pjenušavi materijal.
The reservoir containing CO2 can be connected to the container such that it can be removed and can comprise an aerosol container or a metal CO2 cartridge containing liquid CO2 accommodated in a cavity in the top wall, bottom wall or side wall of the container. 
Rezervoar koji sadrži CO, može biti tako spojen na spremnik da se može ukloniti te može sadržavati spremnik aerosola ili metalnu CO, patronu koja sadrži tekući COx smješten u utor na gornjoj, donjoj ili bočnoj stranici spremnika.
Heptane (7L/kg) is charged over 7 h and the slurry stirred for 12 h at 22-25°C. 
(d) Heptan (7L/kg) se nanosi tijekom 7 h i smjesa miješa 12 h na 22-25%C.
CaO and MgO in a total amount of from 23 to 33 wt%, and 
CaO i MgO u ukupnoj količini od 23 do 33 tež.%, i
30 minutes prior to testing. 
30 minuta prije testiranja.
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183 for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 wherein it is to be administered in form of an oral dosage during a period of about 2 to about 4 months. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku oralne doze kroz period od oko 2 do oko 4 mjeseca.
In a further aspect, the invention provides a kit for metagenomic identification of DNA present in a sample, comprising a set of primers for the metagenomic amplification of a metagenomic target sequence in the myostatin gene, said metagenomic target sequence being selected to allow for: i) co-amplification of the metagenomic target DNA sequence from a plurality of species using a set of conserved, common primers; ii) the identification of species origin of any amplified metagenomic target DNA on the basis of its sequence; and optionally iii) the relative proportions between the different identified DNA. 
Pribor za metagenomsku identifikaciju DNK prisutne u uzorku hrane, sadržeći set početnica za metagenomsku amplifikaciju metagenomske ciljne sekvence u miostatin genu, navedena metagenomska ciljna sekvenca bivajući odabrana zbog omogućavanja: 1) koamplifikacije metagenomske ciljne DNK sekvence od pluraliteta vrsti koristeći set očuvanih, uobičajenih početnica iz pribora sadržeći početnice koje sadrže ili se sastoje od sekvence SEQ ID NO.
The isolated monoclonal antibody for use according to claim 2, wherein: 
Izolirano monoklonalno antitijelo za uporabu prema patentnom zahtjevu 2, pri čemu:
R10, R20, R30, and R40 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl; 
R10, R20, R30 1 Ro su nezavisno vodik, hidrokarbil ili supstituirani hidrokarbil; Xi je
A pharmaceutical composition, comprising the antibody of claim 13. Use of a transgenic vector for targeted integration, wherein the transgenic vector comprises an inducible expression control region operably linked to a meganuclease-encoding nucleic acid, wherein the use comprises: 
In vitro primjena transgenskog vektora za ciljanu integraciju, pri čemu transgeni vektor sadrži induskcijsku ekspresijsku kontrolnu regiju koju je moguće koja je operabilno povezana s nukleinskom kiselinom koja kodira mjesno specifičnu meganukleazu koja cilja endogeni Ig lokus, pri čemu uporaba obuhvaća:
The organic extract was dried over MgSO4, filtered and evaporated. 
Organski ekstrakt se osuši preko MgSO., filtrira i upari.
When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods for example, chromatographic techniques, chiral HPLC or fractional crystallization. 
Kada se pripremaju dijastereomerni ili enantiomerni produkti, oni se mogu odvojiti primjenom konvencionalnih postupaka, npr., kromatografskim tehnikama, kiralnom HPLC ili frakcijskom kristalizacijom.
One embodiment of the invention provides a compound having Formula I: or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, W is CRw or N, wherein Rw is selected from the group consisting of 
Spoj, naznačen time, da ima formulu I: is ili njegov stereoizomer, tautomer ili farmaceutski prihvatljiva sol, gdje W je CRw ili N, gdje Ry je odabran iz skupine koja sadrži
The drive system according to claim 1, wherein said control unit is adapted to activate the holding brake when a predetermined lower threshold value of a residual charge of said accumulator unit is reached. 
Pogonski i upravljački sustav prema zahtjevu 1, naznačen time, da je navedena upravljačka jedinica prilagođena za osiguravanje spomenutog krila vrata protiv sudara aktivirajući držač kočnice kada je postignuta unaprijed određena niža granična vrijednost spomenute preostale nabojne jedinice akumulatora.
providing an immunoglobulin solution with a concentration of at least 100 g/l, 
pripremanje otopine imunoglobulina s koncentracijom od najmanje 100 g/l; b)
After storage for 2 hours in the dark the content of radioactivity is determined by liquid scintillation counting. 
Nakon spremanja na tamnom mjestu tijekom 2 sata određuje se sadržaj radioaktivnosti pomoću brojenja tekuće scintilacije.